Literature DB >> 18339213

Fibrinolysis or hypercoagulation during radical prostatectomy? An evaluation of thrombelastographic parameters and standard laboratory tests.

S Ziegler1, A Ortu, C Reale, R Proietti, E Mondello, R Tufano, P di Benedetto, G Fanelli.   

Abstract

BACKGROUND AND OBJECTIVES: Radical prostatectomy is at high risk for intraoperative and postoperative bleeding due to surgical trauma, release of urokinase and tissue type plasminogen activator. We conducted this prospective, observational multi-centre study to assess the degree of systemic fibrinolysis or hypercoagulation in the perioperative period. We studied serial changes in standard laboratory values and in thrombelastographic (TEG; Haemoscope Corporation, Skokie, IL, USA) parameters including lysis at 30 and 60 min (LY-30, LY-60), alpha-angle (alpha) and maximum amplitude.
METHODS: In all, 49 patients undergoing radical retropubic prostatectomy in five Italian University Hospitals were included. Blood samples were taken before surgery (T1), at the removal of the prostate (T2), 4 h after surgery (T3) and then 1 day after surgery (T4). Native blood samples were analysed using a thrombelastograph Haemoscope 5000 (Haemoscope Corporation).
RESULTS: We did not see any relevant activation of fibrinolysis during any stage. Intraoperatively, we showed even more activated blood coagulation with consumption of fibrinogen and a reduced TEG percentage clot lysis. Only at the first postoperative sample point we saw a trend towards a more fibrinolytic state indicated by increasing partial thromboplastin time, LY-30 and LY-60 values, and a peak of the fibrin degradation product D-dimers. This is consistent with a normal reaction to the hypercoagulable state before and is unlikely to be due to an intraoperative tissue type plasminogen activator release. We found no evidence of an uncontrolled activation of fibrinolysis on the day after surgery. On the contrary, alpha-values which indicate the rate of clot formation and which increase during hypercoagulation showed the tendency to rise slightly compared with the preoperative value.
CONCLUSION: Neither standard coagulation parameters nor TEG values showed any significant activation of fibrinolysis or of hypercoagulation in the preoperative period. Nevertheless, hypercoagulation seems to have a substantial clinical impact as it has been shown that cardiovascular complications and pulmonary embolism were the most common causes of death after retropubic prostatectomy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18339213     DOI: 10.1017/S0265021508003852

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  4 in total

1.  Using Haemocoagulase Agkistrodon in Patients Undergoing Transurethral Plasmakinetic Resection of the Prostate: A Pilot, Real-World, and Propensity Score-Matched Study.

Authors:  Cong Zhu; Lan Yang; Hao Zi; Bing-Hui Li; Qiao Huang; Meng-Xin Lu; Xiao-Dong Li; Xuan-Yi Ren; Hua Tao; Hankun Hu; Xian-Tao Zeng
Journal:  Biomed Res Int       Date:  2022-06-22       Impact factor: 3.246

2.  Efficacy of tranexamic acid in decreasing primary hemorrhage in transurethral resection of the prostate: A novel combination of intravenous and topical approach.

Authors:  Abhimanyu Gupta; Shivam Priyadarshi; Nachiket Vyas; Govind Sharma
Journal:  Urol Ann       Date:  2021-07-14

3.  Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial.

Authors:  Antonella Crescenti; Giovanni Borghi; Elena Bignami; Gaia Bertarelli; Giovanni Landoni; Giuseppina Maria Casiraghi; Alberto Briganti; Francesco Montorsi; Patrizio Rigatti; Alberto Zangrillo
Journal:  BMJ       Date:  2011-10-19

4.  Can tranexamic acid reduce the blood transfusion rate in patients undergoing percutaneous nephrolithotomy? A systematic review and meta-analysis.

Authors:  Zhenghao Wang; Xiao He; Yunjin Bai; Jia Wang
Journal:  J Int Med Res       Date:  2020-04       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.